Register for free to
view the full innovation profile.
IMPDH inhibitor drugs to be developed and used to fight against C.pavrum and applied to other treatments for transplant rejection, autoimmune diseases, viral disease and cancers.
About
Since IMPDH plays a role in immune cells, metabolic events and viral replication, IMPDH inhibitors are useful drugs in the treatment of transplant rejection, autoimmune disease, viral diseases and cancers. All parasitic protozoa lack purine biosynthetic enzymes and must salvage purines from their hosts, making the IMPDH pathway an attractive target for developing anti-protozoa drugs currently in Phase I of it's clinical study currently underway, tracking blood glucose and GI responses over 4 weeks. As of this time there are No effective drug treatments that exist for cryptosporidiosis. With these compounds being more potent than those previously reported.
Key Benefits
- Provides first potential treatment for the C. parvum parasite - Can be developed and adapted to many other treatment applications -Can be the first effective drug on the market ever to effectively treat cryptosporidiosis
Applications
This can be applied to the pharmaceutical fields of research to aid and help advance research in areas of multiple treatments. With IMPDH inhibitors displaying Displaying a greater potency than paromomycin, the current gold standard for anti-cryptosporidial activities